Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.

Hiasto KawakamiKazumasa FujitaniJin MatsuyamaYusuke AkamaruShigeyuki TamuraShunji EndoYutaka KimuraYouichi MakariTakao TamuraNaotoshi SugimotoDaisuke SakaiToshimasa TsujinakaMasahiro GotoYukinori KurokawaToshio ShimokawaTaroh Satohnull null

Published in: International journal of clinical oncology (2020)

The HERBIS-2 trial was registered with UMIN-CTR as UMIN000006105.

Keyphrases

phase iii
locally advanced
gestational age
open label
clinical trial
study protocol
phase ii
phase ii study
squamous cell carcinoma
double blind
placebo controlled
metastatic colorectal cancer